Sphera Funds Management LTD. Takes $4.13 Million Position in Sutro Biopharma Inc (STRO)

Sphera Funds Management LTD. bought a new stake in shares of Sutro Biopharma Inc (NASDAQ:STRO) during the third quarter, HoldingsChannel.com reports. The fund bought 275,000 shares of the company’s stock, valued at approximately $4,125,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of STRO. Dean Capital Investments Management LLC purchased a new position in Sutro Biopharma during the 3rd quarter valued at about $592,000. JPMorgan Chase & Co. purchased a new position in Sutro Biopharma during the 3rd quarter valued at about $1,501,000. Monashee Investment Management LLC purchased a new position in Sutro Biopharma during the 3rd quarter valued at about $1,575,000. AWM Investment Company Inc. purchased a new position in Sutro Biopharma during the 3rd quarter valued at about $1,672,000. Finally, Jennison Associates LLC purchased a new position in Sutro Biopharma during the 3rd quarter valued at about $2,250,000. 39.97% of the stock is currently owned by institutional investors and hedge funds.

In other news, major shareholder Merck & Co., Inc. purchased 666,666 shares of the stock in a transaction dated Monday, October 1st. The shares were acquired at an average cost of $15.00 per share, for a total transaction of $9,999,990.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link.

A number of research analysts have commented on STRO shares. Piper Jaffray Companies started coverage on shares of Sutro Biopharma in a research report on Monday, October 22nd. They set an “overweight” rating and a $23.00 target price on the stock. JMP Securities started coverage on shares of Sutro Biopharma in a research report on Monday, October 22nd. They set an “outperform” rating and a $28.00 target price on the stock. Wedbush started coverage on shares of Sutro Biopharma in a research report on Monday, October 22nd. They set an “outperform” rating and a $20.00 target price on the stock. Finally, Cowen started coverage on shares of Sutro Biopharma in a research report on Monday, October 22nd. They set an “outperform” rating on the stock.

NASDAQ:STRO opened at $10.27 on Friday. Sutro Biopharma Inc has a fifty-two week low of $9.50 and a fifty-two week high of $15.90.

Sutro Biopharma (NASDAQ:STRO) last released its quarterly earnings results on Wednesday, November 14th. The company reported ($21.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($21.10). The firm had revenue of $7.84 million for the quarter. As a group, analysts expect that Sutro Biopharma Inc will post -4.63 EPS for the current year.

TRADEMARK VIOLATION WARNING: This news story was originally posted by WKRB News and is owned by of WKRB News. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at https://www.wkrb13.com/2018/12/08/sphera-funds-management-ltd-takes-4-13-million-position-in-sutro-biopharma-inc-stro.html.

About Sutro Biopharma

Sutro Biopharma, Inc operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers.

Featured Story: Consumer behavior in bull markets

Want to see what other hedge funds are holding STRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sutro Biopharma Inc (NASDAQ:STRO).

Institutional Ownership by Quarter for Sutro Biopharma (NASDAQ:STRO)

Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply